Lysogene will host a live webcast on Wednesday, November 23, 2022 at 1:30 pm CET to provide updates and topline results from the Phase 2/3 AAVance study evaluating LYS-SAF302, an investigational gene therapy for the treatment of MPS IIIA. Participants may register for the webcast by via the following website https://channel.royalcast.com/lysogene/#!/lysogene/20221123_1 Presentation is available here. […]